Resveratrol and cardiovascular system-the unfulfilled hopes.
Małgorzata ChudzińskaDaniel RogowiczŁukasz WołowiecJoanna BanachSławomir SielskiRobert BujakAnna SinkiewiczGrzegorz GrześkPublished in: Irish journal of medical science (2020)
Despite numerous articles and clinical studies, the convincing beneficial mechanisms of resveratrol as well as its health-promoting effects in cardiovascular diseases have not been clearly confirmed in humans. Therefore, there is a need for further clinical studies, especially randomized, double-blind, placebo-controlled trials to objectively confirm the possible health-promoting effects of this substance and to determine both the efficacy and safety, and possible therapeutic potential.
Keyphrases
- placebo controlled
- double blind
- phase iii
- healthcare
- clinical trial
- public health
- phase ii
- cardiovascular disease
- study protocol
- health information
- phase ii study
- mental health
- physical activity
- open label
- health promotion
- squamous cell carcinoma
- human health
- type diabetes
- climate change
- cardiovascular risk factors
- coronary artery disease
- radiation therapy
- cardiovascular events